A separate analysis in Nature Medicine found that retatrutide produced significant reductions in liver fat content in participants with metabolic dysfunction-associated steatotic liver disease (MASLD), suggesting benefits beyond simple weight reduction
Most data comes from: That said, Dihexa is being used off-label in clinical practices, and practitioners continue to monitor real-world outcomes in: Despite promising data, Dihexa has not yet completed the rigorous phases needed for FDA approval
It also has anti-inflammatory properties that help calm the skin and reduce oxidative damage
However, this hypothesis has been challenged
Hormones or genetics are the main triggers for the patches of discoloration known as melasma
For multi-dose vials that will last weeks, some researchers use proper reconstitution techniques and sterile technique consistently to prevent contamination that accelerates degradation